Biotech Billionaire’s Cancer Cure Claim BACKFIRES

A biotech billionaire claimed his bladder cancer drug could cure all cancers, prompting the FDA to slap down the hype with a stern warning that tanked his company’s shares overnight.

Story Snapshot

FDA warns ImmunityBio on March 13, 2026, for misleading Anktiva claims by Patrick Soon-Shiong on podcast and TV ad.
Soon-Shiong touted Anktiva as universal cancer cure, vaccine, and radiation shield despite approval only for specific bladder cancer.
Company shares plunge over 24% on March 24, 2026; podcast link scrubbed from website.
Highlights clash between biotech innovation drive and FDA patient safety enforcement under Trump administration.

Biotech Billionaire’s Bold Cancer Claims

Patrick Soon-Shiong, ImmunityBio’s executive chairman and chief medical officer, appeared on The Sean Spicer Show podcast in January 2026. He declared Anktiva “can treat all cancers” and sits “on the path to curing cancer.” He also positioned it as a “BioShield” preventing radiation-induced cancers. These statements ignored Anktiva’s narrow 2024 FDA approval for non-muscle invasive bladder cancer unresponsive to BCG therapy. The FDA flagged them as misleading for lacking risk disclosures and implying unproven broad uses.

FDA Warning Letter Details Violations

The FDA sent a warning letter dated March 13, 2026, to ImmunityBio CEO Richard Adcock. It cited a TV ad labeling Anktiva a “Cancer Therapeutic Vaccine (BioShield)” without mentioning risks. Regulators criticized promotion of unapproved subcutaneous injection and false suggestions of universal efficacy or prevention. Anktiva, an IL-15 receptor agonist boosting NK and CD8+ T cells, lacks data for these expansive claims. The agency demanded corrections within 15 days to protect vulnerable cancer patients.

Company’s Immediate Fallout and Response

ImmunityBio shares dropped more than 24% after the warning letter posted online on March 24, 2026. The company removed the podcast link from its website that same day. Spokesperson Sarah Singleton stated ImmunityBio takes the warning “very seriously” and will work cooperatively with the FDA. No further comments came from Soon-Shiong. Anktiva remains approved solely for BCG-unresponsive NMIBC with CIS, stalling broader expansion bids.

Soon-Shiong’s History of FDA Clashes

Soon-Shiong founded ImmunityBio through acquisitions like NantWorks. He holds deep financial ties, including a $30 million promissory note from affiliated Nant Capital in 2023. In 2025, the FDA rejected Anktiva expansions for lung and pancreatic cancers due to weak data. Soon-Shiong then misrepresented a follow-up FDA meeting in January 2026, distorting outcomes per STAT News analysis. This pattern of executive-led hype precedes the latest violations.

FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong https://t.co/Y4YOCWmd3e

— The Morning Call (@mcall) March 24, 2026

Common sense aligns with FDA enforcement here. Overpromising cures preys on desperate patients, eroding trust in real breakthroughs. Conservative values prize accountability; regulators rightly curb billionaire influence when facts don’t support the flash. ImmunityBio’s niche approval demands precise marketing, not cure-all fantasies that risk lives and investor funds.

Broader Impacts on Patients and Industry

Cancer patients face false hope from such claims, as the disease ranks second in U.S. deaths. NMIBC sufferers worry about access amid uncertainty. Investors suffer stock hits, with IBRX dipping under $5 despite M&A whispers. The Trump-era FDA ramps up scrutiny on podcast and TV promotions, deterring biotech “cure-all” narratives. Long-term, expect delayed approvals, potential fines, and chilled funding for aggressive expansions.